Gilead Sciences
Foster City, California, USA
Gilead Sciences is a pharmaceutical company.
How We Help
Problem Statement
Gilead Sciences addresses unmet medical needs by discovering, developing, and commercializing innovative medicines, particularly for serious and life-threatening diseases.
Core Technology
Initially focused on antiviral therapeutics using nucleotide and nucleoside analogue chemistry. Current capabilities include antiviral chemistry expertise, cell and antibody-drug conjugate (ADC) capabilities, and leverages cloud, data, and AI/ML for drug discovery and development.
Key Differentiators
Innovative pipeline and breakthrough therapies (especially in antivirals for HIV and hepatitis C), R&D leadership, specialized expertise in antiviral chemistry and expanding oncology capabilities, patient-centric approach, strategic partnerships, global presence and access, commitment to health equity, and operational excellence.
Clinical Focus
Development of therapies for viral diseases (HIV/AIDS, hepatitis), various cancers, and inflammatory conditions, with a strong emphasis on antiviral chemistry, cell, and antibody-drug conjugate technologies.
Target Customers
Patients (indirectly), physicians, hospitals, and health systems globally.
Product Stage
Mature
Company Info
- Business Model
- Research-based, innovation-driven biopharmaceutical company. Discovers, develops, and commercializes innovative medicines, primarily through direct sales of proprietary drugs and therapies, licensing agreements, and collaboration partnerships. Employs a vertically integrated business model.
- Founded
- 1987
- Total Funding
- 88,250,000
- Website
- www.gilead.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
OM336 (gamgertamig) has received FDA Fast Track and Orphan Drug Designation. Clinical trials demonstrated a single-tablet regimen of bictegravir and lenacapavir maintained virological suppression in people with HIV. The FDA approved a label update for Kite's Yescarta.
MedStartr Index Score
?What do you think of Gilead Sciences?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.